PTLD risk associated with HCV status at the time of transplantation among 210 763 solid organ transplant recipients
| . | HCV+ . | HCV status unknown . |
|---|---|---|
| Unadjusted | 0.63 (0.51-0.78) | 0.88 (0.76-1.02) |
| Adjusted for age, sex, race/ethnicity, and education | 0.84 (0.68-1.05) | 0.84 (0.73-0.98) |
| Additional adjustments | ||
| Organ type (HL, KP, liver, other) | 0.78 (0.62-0.97) | 0.81 (0.70-0.94) |
| Indication for transplantation | 0.83 (0.65-1.05) | 0.84 (0.72-0.97) |
| Degree of HLA mismatch (score: 0-6) | 0.75 (0.61-0.94) | 0.81 (0.70-0.94) |
| Donor type (cadaveric/living) | 0.78 (0.63-0.97) | 0.82 (0.71-0.95) |
| Use of any induction medication | 0.85 (0.68-1.05) | 0.86 (0.74-1.00) |
| Use of specified induction medications: polyclonal antibodies or other | 0.85 (0.69-1.06) | 0.86 (0.74-1.00) |
| Use of any maintenance medication | 0.85 (0.68-1.05) | 0.86 (0.74-1.00) |
| Use of specified maintenance medications: steroids, antimetabolites, calcineurin inhibitor, or TOR inhibitors | 0.85 (0.69-1.06) | 0.85 (0.73-0.99) |
| Use of any antirejection medication | 0.84 (0.68-1.04) | 0.84 (0.73-0.98) |
| Use of specified antirejection medications: polyclonal antibodies or other | 0.84 (0.68-1.04) | 0.84 (0.73-0.98) |
| Use of any induction, maintenance, and antirejection immunosuppresion medications | 0.84 (0.68-1.05) | 0.87 (0.75-1.01) |
| Use of specified induction, maintenance, and antirejection immunosuppression medications | 0.85 (0.69-1.06) | 0.87 (0.75-1.01) |
| . | HCV+ . | HCV status unknown . |
|---|---|---|
| Unadjusted | 0.63 (0.51-0.78) | 0.88 (0.76-1.02) |
| Adjusted for age, sex, race/ethnicity, and education | 0.84 (0.68-1.05) | 0.84 (0.73-0.98) |
| Additional adjustments | ||
| Organ type (HL, KP, liver, other) | 0.78 (0.62-0.97) | 0.81 (0.70-0.94) |
| Indication for transplantation | 0.83 (0.65-1.05) | 0.84 (0.72-0.97) |
| Degree of HLA mismatch (score: 0-6) | 0.75 (0.61-0.94) | 0.81 (0.70-0.94) |
| Donor type (cadaveric/living) | 0.78 (0.63-0.97) | 0.82 (0.71-0.95) |
| Use of any induction medication | 0.85 (0.68-1.05) | 0.86 (0.74-1.00) |
| Use of specified induction medications: polyclonal antibodies or other | 0.85 (0.69-1.06) | 0.86 (0.74-1.00) |
| Use of any maintenance medication | 0.85 (0.68-1.05) | 0.86 (0.74-1.00) |
| Use of specified maintenance medications: steroids, antimetabolites, calcineurin inhibitor, or TOR inhibitors | 0.85 (0.69-1.06) | 0.85 (0.73-0.99) |
| Use of any antirejection medication | 0.84 (0.68-1.04) | 0.84 (0.73-0.98) |
| Use of specified antirejection medications: polyclonal antibodies or other | 0.84 (0.68-1.04) | 0.84 (0.73-0.98) |
| Use of any induction, maintenance, and antirejection immunosuppresion medications | 0.84 (0.68-1.05) | 0.87 (0.75-1.01) |
| Use of specified induction, maintenance, and antirejection immunosuppression medications | 0.85 (0.69-1.06) | 0.87 (0.75-1.01) |
Data are HR (95% CI). HCV− recipients were used as the referent group in all analyses.
HL indicates heart and/or lung; and KP, kidney and/or pancreas.